CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
CVI Accepts, published online ahead of print on 3 October 2007
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00100-07v1
14/12/1644    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuan, F. F
Right arrow Articles by Sullivan, J. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuan, F. F
Right arrow Articles by Sullivan, J. S

 Previous Article  |  Next Article 

Clin. Vaccine Immunol. doi:10.1128/CVI.00100-07
Copyright (c) 2007, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

CD14-159CC, another risk genotype for severe SARS-CoV infection

Fang F Yuan*, Ingrid Boehm, Paul KS Chan, Katherine Marks, Julian W Tang, David SC Hui, Joseph JY Sung, Wayne B Dyer, Andrew F Geczy, and John S Sullivan

Australian Red Cross Blood Service-Endeavour, Sydney, NSW 2000, Australia; Department of Microbiology, The Chinese University of Hong Kong, Hong Kong; Research Unit of Transfusion Medicine and Immunogenetics, Faculty of Medicine, University of Sydney; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong; Stanley Ho Centre for Emerging Infectious Diseases, School of Public Health, The Chinese University of Hong Kong, Hong Kong

* To whom correspondence should be addressed. Email: fyuan{at}arcbs.redcross.org.au.


  Abstract

To investigate if other genetic factors of innate immunity might influence susceptibility and/or progression in individuals infected with SARS, we further evaluated CD14 gene polymorphism in 198 Hong Kong blood donors and 152 Hong Kong SARS patients who were previously genotyped for Fc{gamma}RIIA polymorphisms. The prevalence of the CD14-159CC was significantly higher in the severe SARS patients than in the mild SARS group or controls (31% vs. 15% or 20%; P = 0.029; OR: 2.74; 95% CI1.15-6.57 or P = 0.04; OR: 2.41; 95% CI 1.05-5.54, respectively), and both CD14-159CC and Fc{gamma}RIIA-RR131 are risk genotypes for severe SARS-CoV infection.






Home Help [Feedback] [For Subscribers] [Archive] [Search] --
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.